Patent ID: 9393311
Filing Date: 2016-07-19
CPC Classification: A61K,C08G

Claim Text:
1. An intravaginal drug delivery ring comprising at least two pharmaceutically active substances wherein the pharmaceutically active substances are tenofovir and UC781, and a polyurethane copolymer, wherein the copolymer has the structure according to formula (I): wherein, SME1 and SME2 can be the same or different and denote a surface modifying end-group comprising a methylpolyethylene glycyol (MPEG), having a number average molecular weight ranging from 200 to 8000, linked to the polymer via a urethane or urea bond resulting from the reaction of an amine- or alcohol-terminated surface modifying end group with an isocyanate group; SS1, SS2, and SS3 denote soft-segments, wherein SS 1 is a polyether diol selected from polyethylene oxide (PEO) diol, polytetramethylene oxide (PTMO) diol, polyhexamethylene oxide diol (PHMO), polypropylene oxide (PPO) diol, copolymer of ethylene glycol and propylene glycol (PEG-co-PPO) diol, and mixtures thereof; SS2 is a hydroxyl or amine-terminated silicone polymer having a number average molecular weight ranging from 500 to 5000 g/mol; and SS3 is a soft-segment selected from polycarbonate diol and polyester diol, and mixtures thereof; HS denotes a hard-segment comprising a diisocyanate selected from the group consisting of hexamethylene diisocyanate (HMDI) and isophorone diisocyanate (IPDI) and combinations thereof, x, y and z are the same or different and each is an integer equal to or greater than zero and at least two of x, y and z are not zero; and wherein the copolymer has a number average molecular weight ranging from 50,000 to 350,000 g/mol and a swollen hardness of at least 30 A, and wherein two or more pharmaceutically active substances are homogeneously distributed throughout the polyurethane copolymer.